Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy

Annals of Neurology

Volumn 45, Issue 4, 1999, Pages 444-450

  Vainionpää, Leena K ^a   Rättyä, Johanna ^a   Knip, Mikael ^a   Tapanainen, Juha S ^a   Pakarinen, Arto J ^a   Lanning, Peter ^a   Tekay, Aydin ^a   Myllylä, Vilho V ^a   Isojärvi, Jouko I T ^a  

^a UNIVERSITY OF OULU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; OXCARBAZEPINE; SOMATOMEDIN BINDING PROTEIN 1; TESTOSTERONE; VALPROIC ACID;

ADOLESCENT; ANTICONVULSANT THERAPY; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; EPILEPSY; FEMALE; HUMAN; HYPERANDROGENISM; NEUROENDOCRINOLOGY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PUBERTY; SCHOOL CHILD; TESTOSTERONE BLOOD LEVEL;

EID: 0345291177     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8249(199904)45:4<444::AID-ANA5>3.0.CO;2-6     Document Type: Article

References (28)

1. Davis R, Peters DH, McTavish D. Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1994;47:332-372
2. Morton LD, Pellock JM. Diagnosis and treatment of epilepsy in children and adolescents. Drugs 1996;51:399-414
3. Scheuer ML, Pedley TA. The evaluation and treatment of seizures. Current concepts. N Engl J Med 1990;323:1468-1474
4. Dam M, Ekberg R, Løning Y, et al. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989;3: 70-76
5. Isojärvi JIT, Laatikainen TJ, Pakarinen AJ, et al. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993;329:1383-1388
6. Isojärvi JIT, Laatikainen TJ, Knip M, et al. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996;39:579-584
7. Egger J, Brett EM. Effects of sodium valproate in 100 children with special reference to weight. BMJ 1981;283:577-581
8. Breum L, Astrup A, Gram L., et al. Metabolic changes during treatment with valproate in humans: implication for untoward weight gain. Metabolism 1992;41:666-670
9. Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 1989;30:389-399
10. Greulich WW, Pyle SI. Radiographic atlas of skeletal development of the hand and wrist. Stanford: California: Stanford University Press, 1959
11. Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child 1976;51:170-179
12. Adams J, Polson DW, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. BMJ 1986:293:355-358
13. Andersen L, Dinesen B, Jørgensen PN, et al. Enzyme immunoassay for intact human insulin in serum or plasma. Clin Chem 1993;39:578-582
14. Lundberg B, Nergårdh A, Ritzén EM, Samuelsson K. Influence of valproic acid on the gonadotropin-releasing hormone test in puberty. Acta Paediatr Scand 1986;75:787-792
15. Potau N, Ibañez L, Riqué S, Carrascosa A. Pubertal changes in insulin secretion and peripheral insulin sensitivity. Horm Res 1997;48:219-226
16. Nobels F, Dewailly D. Puberty and polycystic ovarian syndrome: the insulin /insulin-like growth factor I hypothesis. Fertil Steril 1992;58:655-666
17. Magoffin DA, Kurtz KM, Erickson GF. Insulin-like growth factor-I selectively stimulates cholesterol side-chain cleavage expression in ovarian theca-interstitial cells. Mol Endocrinol 1990;4:489-496
18. Duleba AJ, Spaczynski RZ, Olive DL. Insulin and insulin-like growth factor I stimulate the proliferation of human ovarian theca-interstitial cells. Fertil Steril 1998;69:335-340
19. Juul A, Bang P, Hertel NT, et al. Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab 1994;78:744-752
20. Juul A, Dalgaard P, Blum WF, et al. Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation. J Clin Endocrinol Metab 1995;80:2534-2542
21. Löppönen T, Saukkonen A-L, Setlo W, et al. Reduced levels of growth hormone, insulin-like growth factor-I and binding protein-3 in patients with shunted hydrocephalus. Arch Dis Child 1997;77:32-37
22. Herzog AG, Seibel MM, Schomer DL, et al. Reproductive endocrine disorders in women with partial seizures of temporal lobe origin. Arch Neurol 1986;43:341-346
23. Bilo L, Meo R, Nappi C, et al. Reproductive endocrine disorders in women with primary generalized epilepsy. Epilepsia 1988;29:612-619
24. Isojärvi JIT, Rättyä J, Myllylä VV, et al. Valproate, lamotrigine and insulin-mediated risks in women with epilepsy. Ann Neurol 1998;43:446-451
25. Olsson I, Hagberg G. Epidemiology of absence epilepsy III. Clinical aspects. Acta Paediatr Scand 1991;80:1066-1072
26. Grünewald RA, Panayiotopoulos CP. Juvenile myoclonic epilepsy. A review. Arch Neurol 1993;50:594-598
27. Panayiotopoulos CP, Obeid T, Tahan AR. Juvenile myoclonic epilepsy: a 5-year prospective study. Epilepsia 1994;35:285-296
28. Besag FMC, Wallace SJ, Dulac O, et al. Lamotrigine for the treatment of epilepsy in childhood. J Pediatr 1995;127:991-997